Information  X 
Enter a valid email address

Company Name matching 'Biofrontera AG'

Date
Time Source
Company
Announcement
10 Oct 2019 10:15 am EQS     Biofrontera AG ​​​​​​​Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
16 Feb 2016 1:58 pm RNS Report Factsheet Biofrontera AG (0DOL) Private Placement
11 Feb 2016 3:30 pm RNS Report Factsheet Biofrontera AG (0DOL) Phase III studies update
28 Jan 2016 10:28 am RNS Report Factsheet Biofrontera AG (0DOL) Excellent results in Ameluz BCC clinical study
26 Jan 2016 9:49 am RNS Report Factsheet Biofrontera AG (0DOL) FDA completes Ameluz NDA mid-cycle review
20 Jan 2016 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Notice of Cancellation from Trading on AIM
07 Jan 2016 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) CE Marking Granted for IndoorLux� Collaboration
31 Dec 2015 11:57 am RNS Report Factsheet Biofrontera AG (0DOL) Total Voting Rights
23 Dec 2015 2:30 pm RNS Report Factsheet Biofrontera AG (0DOL) FDA Grants Small Business Waiver of US$2.3m
10 Dec 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Issue of equity and total voting rights
07 Dec 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Marketing approval for Ameluz� in Switzerland
23 Nov 2015 3:05 pm RNS Report Factsheet Biofrontera AG (0DOL) Result of Open Offer and Private Placement
20 Nov 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) 3rd Quarter Report
19 Nov 2015 8:00 am RNS Report Factsheet Biofrontera AG (0DOL) Final patient visit in Phase III trial for BCC
12 Nov 2015 1:00 pm RNS Report Factsheet Biofrontera AG (0DOL) Notice of Q3 Results
11 Nov 2015 12:00 pm RNS Report Factsheet Biofrontera AG (0DOL) Business Operations on Track
05 Nov 2015 11:32 am RNS Report Factsheet Biofrontera AG (0DOL) Further re: Subscription Price of New Shares
28 Oct 2015 3:23 pm RNS Report Factsheet Biofrontera AG (0DOL) Further re: Open Offer and Private Placement
27 Oct 2015 11:31 am RNS Report Factsheet Biofrontera AG (0DOL) Open Offer and Private Placement
02 Oct 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) FDA shortens review period for Ameluz
22 Sep 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Excellent long term results of Phase III trial
14 Sep 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) FDA accepts filing of Ameluz� and BF-RhodoLED�
12 Sep 2015 12:30 am GNW Report Factsheet Biofrontera AG (0DOL) Ad hoc: Biofrontera AG - FDA accepts filing of Ameluz® and BF-RhodoLED® application
01 Sep 2015 7:03 am RNS Report Factsheet Biofrontera AG (0DOL) Result of AGM
14 Aug 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Half Year Results
07 Aug 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Notice of Results
22 Jul 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Appointment of Chief Commercial Officer
20 Jul 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Belixos� Protect product launch
17 Jul 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Notice of AGM
13 Jul 2015 9:45 am RNS Report Factsheet Biofrontera AG (0DOL) FDA New Drug Application submitted for Ameluz�
22 Jun 2015 7:00 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera completes final steps ahead of FDA New Drug Application in the USA
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Final stage completed ahead of FDA submission
19 Jun 2015 6:10 pm RNS Report Factsheet Biofrontera AG (0DOL) Issue of equity and total voting rights
29 May 2015 7:00 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera delivers excellent business development in Q1
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Strong Performance for Q1 2015
28 May 2015 7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Result of Open Offer & Private Placement
27 May 2015 9:28 pm GNW Report Factsheet Biofrontera AG (0DOL) Ad hoc: Biofrontera AG - 1,377,272 shares placed in capital increase
26 May 2015 7:01 am RNS Report Factsheet Biofrontera AG (0DOL) Notice of First Quarter Results 2015
22 May 2015 3:18 pm GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera AG: Notice of First Quarter Results 2015
06 May 2015 8:17 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera delivers excellent results from the Phase III study for field therapy of actinic keratosis for publication
  7:02 am RNS Report Factsheet Biofrontera AG (0DOL) Publication of PIII Study for Actinic Keratosis
27 Apr 2015 2:58 pm RNS Report Factsheet Biofrontera AG (0DOL) Further re Open Offer and Private Placement
23 Apr 2015 1:36 pm RNS Report Factsheet Biofrontera AG (0DOL) Open Offer and Private Placement
  1:23 pm GNW Report Factsheet Biofrontera AG (0DOL) Ad hoc: Biofrontera AG resolves on capital increase
20 Apr 2015 7:00 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera establishes subsidiary in the US
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) US subsidiary and CEO US Operations Appointed
17 Apr 2015 7:00 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera starts with robust growth into the new year
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Q1 Preliminary Trading Update
10 Apr 2015 7:00 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera AG: Biofrontera significantly increases its turnover in Germany in 2014
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Final Results
08 Apr 2015 7:00 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera stabilizes shareholder structure
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Off Market Block Trade Completed
30 Mar 2015 7:01 am GNW Report Factsheet Biofrontera AG (0DOL) Notice of Annual Results 2014
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Notice of Results
25 Mar 2015 7:01 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera starts Sales and Marketing of Ameluz® in Spain
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Sales and Marketing of Ameluz� in Spain
26 Jan 2015 7:00 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz®
  7:00 am RNS Report Factsheet Biofrontera AG (0DOL) Ameluz Belgium launch and Clinical Trials Update
22 Jan 2015 8:00 am RNS Report Factsheet Biofrontera AG (0DOL) Change of Adviser
05 Dec 2014 9:00 am GNW Report Factsheet Biofrontera AG (0DOL) Biofrontera launches new addition Belixos®...


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t